EST Outlook Therapeutics (OTLK) files to sell 7.07M shares of common stock for holdersDiscover the Best Stocks and Maximize Your ...

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval ...

ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...